search

Active clinical trials for "Monoclonal Gammopathy of Undetermined Significance"

Results 1-10 of 60

Rifaximin in Patients With Monoclonal Gammopathy

IgA Monoclonal GammopathyIgG Monoclonal Gammopathy8 more

This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

Recruiting10 enrollment criteria

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

Monoclonal Gammopathy

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.

Recruiting27 enrollment criteria

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With...

Multiple MyelomaMonoclonal Gammopathy of Renal Significance

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.

Recruiting61 enrollment criteria

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma...

Prostate CancerMultiple Myeloma2 more

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

Recruiting24 enrollment criteria

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma

The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma. The names of the study drug involved in this study is: Metformin, extended release Placebo ( a pill that has no active ingredients)

Recruiting38 enrollment criteria

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy...

Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance

The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.

Recruiting21 enrollment criteria

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering...

Monoclonal GammopathySmoldering Multiple Myeloma

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab

Active51 enrollment criteria

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Aplastic AnemiaHematopoietic and Lymphoid Cell Neoplasm5 more

This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.

Active25 enrollment criteria

Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation...

Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance1 more

This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program. This involves analyzing community reception, screening program methods, reasons patients decided to participate, reasons patients declined participation, and participant views and attitudes. This study also aims to gauge the current and general understanding of MM. This study seeks to recruit participants in the pilot screening program to promote early detection. Participants who have abnormal results will receive patient navigation for further diagnostics and testing.

Recruiting4 enrollment criteria

Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy...

Monoclonal Gammopathy of Uncertain Significance

The objective of this investigator-initiated phase II single-arm open-label clinical trial is to investigate neurological response rate, safety and tolerability of Zanubrutinib 320 mg daily in combination with Rituximab 375 mg/m2 (standard therapy) for the treatment of immunoglobulin M monoclonal gammopathy of unknown significance (IgM MGUS) related polyneuropathy with Myelin Associated Glycoprotein antibodies (anti-MAG). 42 adult patients will be included in two Dutch hospitals (University Medical Center Utrecht and Amsterdam University Medical Center). This trial consists of a 6-month treatment period, after which the hematological response will be evaluated. Adequately responding participants (at least partial response) will be treated for an additional 6 months, after which hematological response will be re-evaluated. Participants with at least a very good partial response will remain on treatment. Non-responding participants will be followed for clinical outcomes only. The total study period per participant will be 36 months.

Not yet recruiting37 enrollment criteria
12...6

Need Help? Contact our team!


We'll reach out to this number within 24 hrs